/ Unknown status临床2/3期IIT A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
100 项与 Gaia Science Pte Ltd. 相关的临床结果
0 项与 Gaia Science Pte Ltd. 相关的专利(医药)
100 项与 Gaia Science Pte Ltd. 相关的药物交易
100 项与 Gaia Science Pte Ltd. 相关的转化医学